Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Vitrolife AB (publ) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $13.30.
Current Consensus is
Buy
The current consensus among 1 investment analysts is to buy stock in Vitrolife AB (publ). This Buy consensus rating has held steady for over two years.
Vitrolife AB (publ) provides assisted reproduction products. It also offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. In addition, the company offers EmbryoScope and time-lapse systems; time-lapse dishes; and evaluation tools for time-lapse systems. The company operates in Europe, the Middle East, India and Africa; Asia; Japan and Pacific; Americas; and Asia. Vitrolife AB (publ) was founded in 1994 and is based in Gothenburg, Sweden.
Read More